UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Takeda Pharmaceutical Ltd ADR (TAK)

Takeda Pharmaceutical Ltd ADR (TAK)
14.08 +0.22 (+1.59%) 14:50 ET [NYSE]
14.07 x 1102 14.08 x 256
Realtime by (Cboe BZX)
14.07 x 1102 14.08 x 256
Realtime 13.90 +0.04 (+0.29%) 08:50 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
13.93
Day High
14.07
Open 13.93
Previous Close 13.86 13.86
Volume 831,867 831,867
Avg Vol 1,744,558 1,744,558
Stochastic %K 85.00% 85.00%
Weighted Alpha -0.95 -0.95
5-Day Change +0.44 (+3.19%) +0.44 (+3.19%)
52-Week Range 12.57 - 15.08 12.57 - 15.08
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,100,784
  • Shares Outstanding, K 3,181,875
  • Annual Sales, $ 29,420 M
  • Annual Income, $ 994,060 K
  • EBIT $ 2,943 M
  • EBITDA $ 11,000 M
  • 60-Month Beta 0.51
  • Price/Sales 1.55
  • Price/Cash Flow 4.24
  • Price/Book 0.89

Options Overview Details

View History
  • Implied Volatility 25.18% ( -17.45%)
  • Historical Volatility 22.12%
  • IV Percentile 17%
  • IV Rank 18.18%
  • IV High 80.58% on 07/10/24
  • IV Low 12.88% on 09/05/24
  • Put/Call Vol Ratio 0.09
  • Today's Volume 271
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 2,727
  • Open Int (30-Day) 2,497

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.80 +9.80%
on 01/23/25
Period Open: 13.10
14.07 -0.11%
on 02/21/25
+0.95 (+7.29%)
since 01/21/25
3-Month
12.80 +9.80%
on 01/23/25
Period Open: 13.33
14.07 -0.11%
on 02/21/25
+0.73 (+5.44%)
since 11/21/24
52-Week
12.57 +11.77%
on 06/20/24
Period Open: 14.74
15.08 -6.80%
on 08/23/24
-0.68 (-4.65%)
since 02/21/24

Most Recent Stories

More News
Cathie Wood Just Doubled Down on This AI Stock. Should You?

The stock is one of the renowned investor’s top holdings.

ARKG : 27.05 (-5.29%)
MRK : 89.09 (+1.61%)
TEM : 69.90 (-8.89%)
ARKK : 60.51 (-5.42%)
TAK : 14.07 (+1.52%)
BNTX : 118.58 (+0.59%)
Here is the Year-End FOMC Outlook

It took a while to get here, but the Fed finally cut interest rates last week. U.S. and European share markets reacted positively to the FOMC policy directive for a 50 bps Fed Funds rate cut. That was...

NPSNY : 53.4050 (+1.86%)
PKG : 206.90 (-1.33%)
TAK : 14.07 (+1.52%)
The Zacks Analyst Blog Highlights Takeda Pharma, Naspers and Packaging Corp. of America

For Immediate ReleaseChicago, IL – September 24, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...

NPSNY : 53.4050 (+1.86%)
PKG : 206.90 (-1.33%)
TAK : 14.07 (+1.52%)
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment.

WVE : 11.12 (-1.85%)
GSK : 36.61 (+0.11%)
TAK : 14.07 (+1.52%)
New Study Reveals How Classical Music Could Revolutionize Depression Care

In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of patients...

ALZN : 0.9825 (-3.68%)
NBIX : 120.19 (+3.51%)
TAK : 14.07 (+1.52%)
AXSM : 137.61 (+6.59%)
BIIB : 140.41 (+2.43%)
3 'Strong Buy'-Rated Stocks to Buy Now on the Dip

These outstanding growth stocks are worth buying on the dip.

AMZN : 215.31 (-3.40%)
$SPX : 6,011.69 (-1.73%)
GEHC : 91.21 (-0.96%)
GD : 243.24 (-1.20%)
OVID : 0.6201 (+9.37%)
TAK : 14.07 (+1.52%)
One Ultra-Cheap High-Yield Dividend Stock to Buy

Now may be a good time for dividend investors to consider loading up on this stock.

TAK : 14.07 (+1.52%)
Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time

There are very good reasons that stocks generally gain in value after a company receives %OrphanDrug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock...

SNY : 54.37 (+0.44%)
TAK : 14.07 (+1.52%)
NRX.VN : 0.610 (+2.52%)
BMY : 55.84 (+0.09%)
NRX : 0.14 (+7.69%)
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. Positive Opinion...

TAK : 14.07 (+1.52%)
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris

One of these high-yield pharma stocks stands out as a better buy right now.

PFE : 26.34 (+1.70%)
TAK : 14.07 (+1.52%)
VTRS : 11.30 (+2.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide...

See More

Key Turning Points

3rd Resistance Point 14.03
2nd Resistance Point 13.97
1st Resistance Point 13.91
Last Price 14.07
1st Support Level 13.79
2nd Support Level 13.73
3rd Support Level 13.67

See More

52-Week High 15.08
Fibonacci 61.8% 14.12
Last Price 14.07
Fibonacci 50% 13.83
Fibonacci 38.2% 13.53
52-Week Low 12.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements